Literature DB >> 9339696

Meta-analysis of the Hachinski Ischemic Score in pathologically verified dementias.

J T Moroney1, E Bagiella, D W Desmond, V C Hachinski, P K Mölsä, L Gustafson, A Brun, P Fischer, T Erkinjuntti, W Rosen, M C Paik, T K Tatemichi.   

Abstract

Our objectives were to investigate the utility of the Hachinski Ischemic Score (HIS) in differentiating patients with pathologically verified Alzheimer's disease (AD), multi-infarct dementia (MID), and "mixed" (AD plus cerebrovascular disease) dementia, and to identify the specific items of the HIS that best discriminate those dementia subtypes. Investigators from six sites participated in a meta-analysis by contributing original clinical data, HIS, and pathologic diagnoses on 312 patients with dementia (AD, 191; MID, 80; and mixed, 41). Sensitivity and specificity of the HIS were calculated based on varied cutoffs using receiver-operator characteristic curves. Logistic regression analyses were performed to compare each pair of diagnostic groups to obtain the odds ratio (OR) for each HIS item. The mean HIS (+/- SD) was 5.4 +/- 4.5 and differed significantly among the groups (AD, 3.1 +/- 2.5; MID, 10.5 +/- 4.1; mixed, 7.7 +/- 4.3). Receiver-operator characteristic curves showed that the best cutoff was < or = 4 for AD and > or = 7 for MID, as originally proposed, with a sensitivity of 89.0% and a specificity of 89.3%. For the comparison of MID versus mixed the sensitivity was 93.1% and the specificity was 17.2%, whereas for AD versus mixed the sensitivity was 83.8% and the specificity was 29.4%. HIS items distinguishing MID from AD were stepwise deterioration (OR, 6.06), fluctuating course (OR, 7.60), hypertension (OR, 4.30), history of stroke (OR, 4.30), and focal neurologic symptoms (OR, 4.40). Only stepwise deterioration (OR, 3.97) and emotional incontinence (OR, 3.39) distinguished MID from mixed, and only fluctuating course (OR, 0.20) and history of stroke (OR, 0.08) distinguished AD from mixed. Our findings suggest that the HIS performed well in the differentiation between AD and MID, the purpose for which it was originally designed, but that the clinical diagnosis of mixed dementia remains difficult. Further prospective studies of the HIS should include additional clinical and neuroimaging variables to permit objective refinement of the scale and improve its ability to identify patients with mixed dementia.

Entities:  

Mesh:

Year:  1997        PMID: 9339696     DOI: 10.1212/wnl.49.4.1096

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  48 in total

1.  An exploration of subgroups of mild cognitive impairment based on cognitive, neuropsychiatric and functional features: analysis of data from the National Alzheimer's Coordinating Center.

Authors:  John J Hanfelt; Joanne Wuu; Ann B Sollinger; Melanie C Greenaway; James J Lah; Allan I Levey; Felicia C Goldstein
Journal:  Am J Geriatr Psychiatry       Date:  2011-11       Impact factor: 4.105

2.  Decreased serum lipids in patients with probable Alzheimer's disease.

Authors:  Orhan Lepara; Amina Valjevac; Azra Alajbegović; Asija Zaćiragić; Emina Nakas-Ićindić
Journal:  Bosn J Basic Med Sci       Date:  2009-08       Impact factor: 3.363

3.  Effects of the Insulin Sensitizer Metformin in Alzheimer Disease: Pilot Data From a Randomized Placebo-controlled Crossover Study.

Authors:  Aaron M Koenig; Dawn Mechanic-Hamilton; Sharon X Xie; Martha F Combs; Anne R Cappola; Long Xie; John A Detre; David A Wolk; Steven E Arnold
Journal:  Alzheimer Dis Assoc Disord       Date:  2017 Apr-Jun       Impact factor: 2.703

4.  Nonmedical treatment of patients with dementia.

Authors:  Edmund Howe
Journal:  Innov Clin Neurosci       Date:  2011-07

5.  Vascular contributions to cognitive impairment.

Authors:  Clinton B Wright; Alan Flores
Journal:  Neurol Clin Pract       Date:  2015-06

6.  The Hachinski ischemic scale and cognition: the influence of ethnicity.

Authors:  Leigh A Johnson; Blair Cushing; Geoffrey Rohlfing; Melissa Edwards; Hedieh Davenloo; Darrin D'Agostino; James R Hall; Sid E O'Bryant
Journal:  Age Ageing       Date:  2013-12-08       Impact factor: 10.668

7.  Executive dysfunction and periventricular diffusion tensor changes in amnesic mild cognitive impairment and early Alzheimer's disease.

Authors:  Ta-Fu Chen; Ya-Fang Chen; Ting-Wen Cheng; Mau-Sun Hua; Hon-Man Liu; Ming-Jang Chiu
Journal:  Hum Brain Mapp       Date:  2009-11       Impact factor: 5.038

8.  [Impact of vascular pathology on survival times of 173 dementia patients--Hachinski's ischemic score as a predictive tool for clinical purposes].

Authors:  S Kissler; S D Hötte; D Lankers; G Juckel; S G Schröder
Journal:  Z Gerontol Geriatr       Date:  2008-02       Impact factor: 1.281

9.  Promoter polymorphisms modulating HSPA5 expression may increase susceptibility to Taiwanese Alzheimer's disease.

Authors:  W-C Hsu; H-K Wang; L-C Lee; H-C Fung; J-C Lin; H-P Hsu; Y-R Wu; L-S Ro; F-J Hu; Y-T Chang; G-J Lee-Chen; C-M Chen
Journal:  J Neural Transm (Vienna)       Date:  2008-09-10       Impact factor: 3.575

10.  Individual cerebral metabolic deficits in Alzheimer's disease and amnestic mild cognitive impairment: an FDG PET study.

Authors:  Angelo Del Sole; Francesca Clerici; Arturo Chiti; Michela Lecchi; Claudio Mariani; Laura Maggiore; Lisa Mosconi; Giovanni Lucignani
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-04-17       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.